PXD054453

PXD054453 is an original dataset announced via ProteomeXchange.

Title	Multi-omic Evaluation of PLK1 Inhibitor—Onvansertib—in Colorectal Cancer Spheroids
Description	Polo-like kinase 1 (Plk1) is a serine/threonine kinase involved in regulating the cell cycle. It is activated by aurora kinase B along with the cofactors Borealin, INCE, and survivn. Plk1 is involved in the development of resistances to chemotherapeutics such as doxorubicin, taxol, and gemcitabine. It has been shown that patients with higher levels of Plk1 have lower survival rates. Onvansertib is a competitive ATP inhibitor for Plk1 in clinical trials for the treatment of tumors and has recently entered a trial for the treatment of KRAS mutant colorectal cancers (CRCs). In this study, we have conducted an untargeted liquid chromatography-mass spectrometry (LC-MS) proteomics study as well as an untargeted lipidomics analysis of HCT 116 spheroids treated with onvansertib over a 72-hour time course experiment. Mass spectrometry Imaging (MSI) showed that onvansertib begins to accumulate after 12-hours, followed by decreasing and clearing out of the spheroid after 72-hours. Proteomics results showed alterations to cell cycle control proteins and an increasing abundance of aurora kinase B and Borealin. The proteomics data also showed alterations to many lipid metabolism enzymes. The MSI lipidomics data showed alterations to PC lipids, with many lipids increasing in abundance over time or increasing until 12-hours of onvansertib treatment and decreasing after that time point. In summary, these results suggest that onvansertib is causing the cells within the spheroid to become stuck in a certain phase of the cell cycle, quite possibly the S phase with the alterations in cell cycle control proteins and PC lipid alterations.
HostingRepository	PRIDE
AnnounceDate	2025-05-07
AnnouncementXML	Submission_2025-05-06_23:15:48.522.xml
DigitalObjectIdentifier
ReviewLevel	Peer-reviewed dataset
DatasetOrigin	Original dataset
RepositorySupport	Unsupported dataset by repository
PrimarySubmitter	Brian Fries
SpeciesList	scientific name: Homo sapiens (Human); NCBI TaxID: 9606;
ModificationList	No PTMs are included in the dataset
Instrument	Q Exactive HF

Revision	Datetime	Status	ChangeLog Entry
0	2024-07-31 10:17:53	ID requested
⏵ 1	2025-05-06 23:15:49	announced

Fries BD, Sekera ER, Holbrook JH, Hummon AB, Multi-Omic Evaluation of PLK1 Inhibitor-Onvansertib-In Colorectal Cancer Spheroids. J Mass Spectrom, 60(5):e5137(2025) [pubmed]

10.1002/jms.5137;

submitter keyword: Colorectal Cancer, Lipidomics, Cell Cycle, Spheroids, Proteomics, Spatial Lipidomics,Plk-1 inhibition, Mass Spectrometry Imaging

Amanda B Hummon
contact affiliation	The Ohio State University, Department of Chemistry and Biochemistry, Columbus, OH 43210
contact email	hummon.1@osu.edu
lab head
Brian Fries
contact affiliation	The Ohio State University
contact email	fries.94@osu.edu
dataset submitter

Dataset FTP location NOTE: Most web browsers have now discontinued native support for FTP access within the browser window. But you can usually install another FTP app (we recommend FileZilla) and configure your browser to launch the external application when you click on this FTP link. Or otherwise, launch an app that supports FTP (like FileZilla) and use this address: ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2025/05/PXD054453

PRIDE project URI

• PRIDE
  1. PXD054453
     1. Label: PRIDE project
     2. Name: Multi-omic Evaluation of PLK1 Inhibitor—Onvansertib—in Colorectal Cancer Spheroids